Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 867 results for score

  1. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  2. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

  3. Sinus tarsi implant insertion for mobile flatfoot (HTG196)

    Evidence-based recommendations on sinus tarsi implant insertion for mobile flatfoot. This involves surgery to insert an implant just above the heel bone, with the aim of correcting the condition and improving symptoms.

  4. Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

    Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  5. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

  6. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  7. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

  8. Coil embolisation of unruptured intracranial aneurysms (HTG63)

    Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.

  9. Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)

    Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.

  10. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  11. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

  12. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  13. Supporting adult carers (QS200)

    This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.

  14. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  15. FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)

    NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .